Effects of Ectoine on Behavior and Candidate Genes Expression in ICV-STZ Rat Model of Sporadic Alzheimer’s Disease

Nilofar Bazazzadegan1, Marzieh Dehghan Shasaltanesh1, Kioomars Saliminejad1, Koorosh Kamali2, Mehdizadeh Nazari1, Reza Hossein Riazi1, Hamid Reza Khorram Khorshid1

1 Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2 Laboratory of Neuro-organic Chemistry, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran.
3 Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.

Abstract

Purpose: Alzheimer’s disease (AD) is pathologically defined by the presence of amyloid plaques and tangles in the brain, therefore, any drug or compound with potential effect on lowering amyloid plaques, could be noticed for AD management especially in the primary phases of the disease. Ectoine constitutes a group of small molecule chaperones (SMCs). SMCs inhibit proteins and other changeable macromolecular structures misfolding from environmental stresses. Ectoine has been reported successfully inhibit insulin amyloid formation in vitro.

Methods: We selected eight genes, DAXX, NFXβ, VEGF, PSEN1, MTAP2, SYP, MAPK3 and TNFα genes which had previously showed significant differential expression in Alzheimer human brain and STZ- rat model. We considered the neuroprotective efficacy by comparing the expression of candidate genes levels in the hippocampus of rat model of Sopradic Alzheimer’s disease (SAD), using qPCR in compound-treated and control groups as well as therapeutic effects at learning and memory levels by using Morris Water Maze (MWM) test.

Results: Our results showed significant down-regulation of Syp, Mapk3 and Tnfa and up-regulation of Vegg in rat’s hippocampus after treatment with ectoine comparing to the STZ-induced group. In MWM, there was no significant change in swimming distance and time for finding the hidden platform in treated comparing to STZ-induced group. In addition, it wasn’t seen significant change in compound-treated comparing to STZ-induced and control groups in memory level.

Conclusion: It seems this compound may have significant effect on expression level of some AD- related genes but not on clinical levels.

Introduction

Alzheimer’s disease (AD) is the most prevalent type of dementia among aged people which is clinically bolded by continuous memory loss and a slow deterioration in cognitive function. AD is neuropathologically specified by loss of neurons and synapses, especially in the hippocampus and cortex, the extracellular agglomeration of neuritic plaques, containing amyloid-β (Aβ) peptide, and the presence of intracellular neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein. The great majority of AD cases are sporadic with aging, type 2 diabetes and apolipoprotein E4 as the essential risk factors. Other mechanisms may commence before the emergence of tau and Aβ pathologies in sporadic AD pathogenesis. These mechanisms include vascular pathology, mitochondrial dysfunction, oxidative stress, hypoxia, insulin resistance, and chronic neuroinflammation.

A nomination causal event in sporadic Alzheimer’s disease (SAD) is distracted brain insulin metabolism. Early abnormalities in brain glucose/energy metabolism are pronounced in parietotemporal and frontal areas with high glucose requirement and high insulin sensitivity which suggests damaged insulin signaling in the pathogenesis of SAD. Injecting streptozotocin, a glucosamine-nitrosourea toxic to pancreatic β cells, into rat brain induced the phosphorylation of the tau protein, amyloid deposits and other SAD symptoms. The aims of management in AD patients have been to ameliorate or at least slow the loss of memory and cognition and to preserve independent function. Acetylcholinesterase suppressors are first-line factors for the remedy of mild to moderate AD. Even though small changes in action mechanisms, these inhibitors have different detrimental effects. The most accepted adverse effects are nausea, vomiting, and diarrhea;
cardiovascular and neurological adverse effects are comparable. The incidence of negative effects is precisely related to the dose administered. Therapy with rivastigmine, donepezil or galantamine as Acetylcholinesterase inhibitors for six months to one year resulted in kind of enhanced cognitive function. Improvements in daily behavior and activities also were eminent in patients cured with one of these factors; however, none of them has a major therapy efficacy and the clinical importance of these effects is ambiguous. Whenever there is no effective treatment for AD, substances with efficient inhibition of the amyloid formation have been sought as drug candidates for AD management. Ectoine is a heterocyclic amino acid or a partially hydrogenated pyrimidine derivative (1,4,5,6-tetrahydro-2-methyl-4-pyrimidinocarboxylic acid). Ectoines are common solutes of aerobic heterotrophic bacteria and compose a class of small molecule chaperones (SMCs). SMCs stack to high intracellular concentrations, inhibiting the misfolding of proteins and other unstable macromolecular structures from environmental stresses. SMCs have already known as eminently effective in maintaining enzymatic activities against heating, freezing and drying. Regarding to a reporting, SMCs like ectoine, betaine, trehalose, citrulline could successfully constrain insulin amyloid formation in vitro (Arora, Ha et al. 2004). All findings propose the effect of SMCs against amyloid formation, which may make them permanent drug candidates for medicating neurodegenerative diseases in the future. Ectoine maintains proteins and enzymes from proteolysis, thermal stress and change of the pH or the salt concentration. Studies showed its potency to maintain various proteins, nucleic acids, membranes and whole cells. Many genes have been reported to be related with AD which they have shown expression changes in Alzheimer model and human brain comparing to normal group. Among them DAXX, NFκβ, VEGF genes with the role in apoptosis, inflammation and angiogenesis showed significant statistical diversity in Alzheimer human brain. Furthermore, Psen1, Map2, Syp, Mapk3 and Tnf α genes with the role in γ-secretase, cytoskeleton, synapses, kinase and inflammation showed significant statistical diversity in STZ rat model. Regarding possible mechanisms of AD like inflammation and oxidative stresses in the brain, and role of various genes in these proceedings, the neuroprotective efficacy was investigated by comparing the expression levels of the mentioned genes in the hippocampus of rat model of SAD using qPCR in treated and untreated groups. Moreover, the remedial effects were considered at learning and memory levels as well.

Materials and Methods

Thirty one mature male Wistar rats with 250-300 g weight were used in this research. They were kept in cage with adequate food and water, in a stable environment at 22°C and 12h light/dark cycle. Animals were distributed into four groups each containing of seven to eight rats: the control group (Eight rats) received no medication and surgery; the sham group (Eight rats) had bilateral intracerebroventricular (ICV) injection of aCSF as the vehicle of STZ; the Alzheimer group (Seven rats) which received bilateral ICV infusion of STZ, and the treated STZ group (Eight rats) which received the compound for fifteen days after modeling as intraperitoneal injection (6 mg/day). All groups except the control one had five recovery days after surgery and before treatment with aCSF, STZ and compound-treated. All procedures were shown in details in Figure 1.

![Figure 1](image_url)
The effects of ectoine on Alzheimer’s disease

Learning and memory examined for all group of rats using Morris Water Maze (MWM) test after treatment. The maze was a round black pool with 150 cm diameter, 60 cm height. Maze was filled with water to a depth of 40 cm with temperature of about 23°C. Four identical spaced places at the circumference of the pool divided the pool into four quadrants, and were used as beginning parts. An escape platform of 10 cm diameter was located 2 cm beneath the surface of the water at a fixed position in the center of one of the quadrants. All rats were participated to a daily session of four training trials for five consecutive days. Each rat was permitted to find the latent platform within sixty seconds. The time spent to detect the platform (Escape latency), the distance each rat swam to find the platform (Path Length) and the swimming speed (Velocity) were recorded. One day after acquisition, a probe test was performed to evaluate memory level by removing platform.

After MWM test, they were immolated and all hippocampi were dissected and reserved in RNA protector solution at -20°C. All processes were performed according to the National Institute of Health Guide for the care and use of laboratory animals. Total RNAs were extracted from hippocampus tissues using UP100H ultrasonic processor (Germany) and RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) conferring to the manufacturer’s protocol. Purity and integrity of RNAs were specified using Nano-drop spectrophotometer and gel electrophoresis. cDNA synthesis was performed using RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, Thermo Fisher Scientific) according to the manufacturer’s protocol. The relative expression levels of the eight genes Daxx, NfkB, Vegf, Psen1, Mtap2, Syp, Mapk3 and Tnf α in rat hippocampus of each group were detected using SYBR green Real Time PCR (Takara SYBR Master Mix (Shiga, Japan) in ABI 7500 Real-time PCR system (Applied Biosystem, Foster city, CA, USA) and). All genes expression normalizations were done by Actb endogenous control. Cycle threshold (Ct) values were used to calculate fold changes in gene expression between groups using REST 2009 software. P-values less than 0.0125 for analysis by REST and in other analysis less than 0.05 were considered statistically significant. MWM test data were analyzed by GraphPad Prism 6 software; Kruskal Wallis (Dunn’s multiple comparisons test) test was used for three recorded factors (escape latency, path length and the swimming speed) in all treated and untreated groups separately during five days.

Results

MWM Test Results

After evaluating the learning and memory level changes using MWM test, our results represented a remarkable gradual decrease in swimming distance and time for finding the hidden platform during five days in all groups, despite of no significant change in these two criteria in -treated comparing to the STZ-induced group during five days, Figure 2a, b and c are representative of MWM test analyses among treated and untreated groups. The swimming speed did not show significant change during five trial days among groups except in STZ group. Probe test results showed no significant memory change in - treated comparing to STZ-induced and control groups (Figure 3).

Expression of Candidate Genes

Syp, Mapk3 and Tnf α genes were down-regulated and Vegf gene was upregulated in rat’s hippocampus after two weeks treatment with comparing to STZ-induced group (Table 1). Statistically significant change (p-value ≤ 0.01) was observed in expression level of Syp, Mapk3, Tnf α and Vegf with decreasing ~ 3, 4.5 and 2- fold in the...
Syp, Mapk3 and Tnf α also increasing 2-fold in Vegf (Figure 4). As it is obvious in Figure 4b, Syp showed no significant up-regulation in the STZ-induced comparing to the control group also, in the -treated comparing to the STZ-induced group there was a significant down-regulation (P-value= 0.002). Also in Figure 4c no significant down-regulation of Mapk3 gene was observed in the STZ-induced comparing to the control group, whereas significant 4.5-fold down-regulation was seen in the -treated comparing to the STZ-induced group (P-value=0.000). As it is obvious in Figure 4d, Tnfa showed significant down-regulation in STZ-induced comparing to control group (P-value= 0.008) the same in -treated versus STZ-induced group with about 2-fold reduction (P-value= 0.01). Figure 4a is representative of the expression of Vegf which was remarkably decreased in the STZ-induced comparing with the control group (P-value= 0), but its expression showed about 2-fold significant up-regulation in the -treated comparing to the STZ-induced group (P-value= 0.001).

**Figure 3.** Inability of rats to find the hidden platform was assessed by probe test. The median with interquartile range of percentage of time spending in target (The zone in which hidden platform located) and opposite zone (The opposite zone of target zone) in the sixth day (four trials) of the test in all treated and control groups. Data were analyzed by GraphPad Prism 6 software.

| Gene     | Ectoine-treated/STZ | p-value | Up or down regulation |
|----------|---------------------|---------|-----------------------|
| Daxx     | 1.9                 | 0.117   | Up-regulation         |
| Nfkb     | 0.7                 | 0.288   | Down - regulation     |
| Vegf     | 2.2                 | 0.001*  | Up-regulation         |
| Syp      | 0.36                | 0.002*  | Down-regulation       |
| Psen1    | 1.05                | 0.823   | Up-regulation         |
| Mapk3    | 0.2                 | 0.000*  | Down-regulation       |
| Mtap2    | 0.6                 | 0.095   | Down-regulation       |
| Tnfa     | 0.45                | 0.017*  | Down-regulation       |

**Table 1.** The table is representative of the eight gene expression levels in Ectoine-treated comparing to the Alzheimer (STZ) group. Asterisk shows significant p-value.

**Discussion**

In this study, we evaluated expression of eight candidate genes (Daxx, Nfkb, Vegf Psen1, Map2, Syp, Mapk3 and Tnf α) for Alzheimer’s disease in RNA level in AD rat model. Our results showed that three genes, Syp, Mapk3 and Tnf α were significantly down-regulated in the treated compared to the STZ-induced group as same as up-regulation of Vegf.

Synaptic loss and dysfunction are reported to be the molecular basis of cognitive deficit in AD.52,53 Chen et al. (2012) reported their finding as notably reduced expression of synaptophysin (Syp) in the hippocampus of icv-STZ mice. Also other Synapse-related genes were found not to be significantly reduced in STZ-induced model even some of them were up-regulated.44 In the present study, as it is obvious in Figure 4b, Syp showed no significant up-regulation in the STZ-induced comparing to the control group also, in the -treated comparing to the STZ-induced group there was a significant down-regulation.

Mitogen-activated protein kinase 3 (Mapk3) is an anti-apoptosis gene which is also involved in neuron plasticity.44 Protein phosphorylation regulates neuronal plasticity, APP processing and tau aggregation.44 Regarding studies, several protein kinases disorder in AD brain or play many roles in the disease. In the study by chen et al. (2012), gene expressions of some AD-related protein kinases showed down-regulation in STZ-induced mice, but only Mapk3 expression change was significant. In our study no significant down-regulation of this gene was observed in the STZ-induced comparing to the control group, whereas significant 4.5-fold down-regulation was seen in the -treated comparing to the STZ-induced group.

Many evidences indicate that neuroinflammation can act as an independent factor at very early stage of AD, where the immune-related genes and cytokines are the important factors. It was reported that proinflammatory cytokines such as TNFα are elevated in the CSF and plasma of AD patients.55 Several biologic medications against TNFα have decreased Aβ deposition, behavioral impairments and inflammation in AD animal models,56-59 which suggest that TNFα is a deleterious agent in AD term and can serve as a reliable AD target. It has been reported that persistent neuronal TNFα expression in 3xTg AD mice led to large amount of neuronal loss.60 In present study, Tnfa showed significant down-regulation in STZ-induced comparing to control group the same in -treated versus STZ-induced group with about 2-fold reduction.

VEGF levels in AD patient have been controversial. According to the available data, it is postulated that reduced VEGF expression might be proved in AD.61 Increased levels of this gene in the hippocampal cortex of AD patients comparing to normal brain were reported.62 Some genetic studies have described that VEGF levels cause neurodegeneration in part by harming neural tissue perfusion.63 Gene array analysis has shown up-regulation of angiogenesis relevant genes in the AD
The effects of ectoine on Alzheimer’s disease

In our study, the expression of Vegf was significantly decreased in the STZ-induced compared to the control group, but its expression showed about 2-fold significant up-regulation in the -treated comparing to the STZ-induced group.

MWM test results represented a significant gradual decrease in swimming distance and time for finding the hidden platform during five training days in all groups, but not significant change was seen in the -treated comparing to the STZ-induced group. Probe test results showed no significant memory change in the compound-treated comparing to the STZ-induced and control groups. According to the previous studies that were reported in the treatment of mild to moderate atopic dermatitis also, ectoine ameliorates ischemia reperfusion injury after intestinal transplantation in rats. Moreover, it causes recovery of neutrophil apoptosis in lung inflammation. Therefore, it can be effective systemically in different diseases.65-67 Regarding previous report, it could successfully prohibit insulin amyloid formation in vitro.38

Figure 4. The expression level of Vegf, Syp, Mapk3 and Tnf-α genes in all treated and control groups are shown in this figure. Significant expression changes of Ectoine-treated group comparing to Alzheimer group were labeled out with asterisk

Conclusion

Finally, regarding to both behavioral and gene expression results, it could be concluded that ectoine may have significant effects on expression level of genes related to angiogenesis, synapsis, kinases and inflammation but, not on clinical level. It is recommended to use transgenic animals that could be very helpful to study gene expression levels in Alzheimer’s disease. Using transgenic animals could be used to study the effects of our compound in prevention of amyloid beta protein and fibrillary tangles formation. Moreover, using different doses of the ectoine maybe have more effective results on Alzheimer disease. Another study that could be helpful is to use the ectoine before construction of Alzheimer models to observe its effects in prevention of the disease. Duration of ectoine administration is another important factor which might be more efficient on Alzheimer treatment and at last route of administration, for instance intravenous (IV) instead of intraperitoneal could be resulted in better management of Alzheimer’s disease.

Acknowledgments

We would like to thank all colleagues specially Dr. Saeed Talebi who helped us in gene expression analysis and Dr. Parvaneh Daneshmand for useful comments. The study was supported by the University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Ethical Issues

Not applicable.

Conflict of Interest

Authors declare no conflict of interest in this study.

References

1. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010;362(4):329-44. doi: 10.1056/NEJMra0909142
2. Selkoe DJ. Alzheimer’s disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001;3(1):75-80. doi: 10.3233/jad-2001-3111
3. Goedert M, Spillantini MG. A century of Alzheimer's disease. *Science* 2006;314(5800):777-81. doi: 10.1126/science.1123814

4. Moreira PI, Honda K, Zhu X, Nunomura A, Casadesus G, Smith MA, et al. Brain and brawn: Parallels in oxidative strength. *Neurology* 2006;66(2 Suppl 1):S97-101. doi: 10.1212/01.wnl.0000192307.15103.83

5. Moreira PI, Santos MS, Seica R, Oliveira CR. Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. *J Neurol Sci* 2007;257(1-2):206-14. doi: 10.1016/j.jns.2007.01.017

6. Moreira PI, Duarte AI, Santos MS, Rego AC, Oliveira CR. An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. *J Alzheimers Dis* 2009;16(4):741-61. doi: 10.3233/JAD-2009-0972

7. Hoyer S. Causes and consequences of disturbances of cerebral glucose metabolism in sporadic alzheimer disease: Therapeutic implications. *Adv Exp Med Biol* 2004;541:135-52.

8. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. *J Neuroinflammation* 2012;9:151. doi: 10.1186/1742-2094-9-151

9. Chételat G. Alzheimer disease: Aβ-independent processes-rethinking preclinical AD. *Nat Rev Neurol* 2013;9(3):123-4. doi: 10.1038/nrneurol.2013.21

10. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other pathologies. *Nat Rev Neurosci* 2011;12(12):723-38. doi: 10.1038/nrn3114

11. Ankarcrona M, Mangialasche F, Winblad B. Rethinking Alzheimer's disease therapy: are mitochondria the key? *J Alzheimers Dis* 2010;20(S2):579-90. doi: 10.3233/JAD-2010-100327

12. Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. *Arch Med Res* 2012;43(8):694-8. doi: 10.1016/j.arcmed.2012.09.009

13. Orešić M, Hyötyläinen T, Herukka S, Sysi-Aho M, Mattila I, Seppänä-Laanasto T, et al. Metabolome in progression to Alzheimer's disease. *Transl Psychiatry* 2011;1:e57. doi: 10.1038/tp.2011.55

14. Kuusisto J, Koivist O, Mykkänen L, Helkala EL, Vanhanen M, Hänninen T, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. *BMJ* 1997;315(7115):1045-9. doi: 10.1136/bmj.315.7115.1045

15. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset Alzheimer disease. *Nat Rev Neurol* 2013;9(1):25-34. doi: 10.1038/nrneurol.2012.236

16. Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR, et al. Insulin is a two-edged knife on the brain. *J Alzheimers Dis* 2009;18(3):483-507. doi: 10.3233/JAD-2009-1155

17. Henneberg N, Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? *Arch Gerontol Geriatr* 1995;21(1):63-74. doi: 10.1016/0167-4943(95)00646-3

18. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. *J Neural Transm (Vienna)* 2002;109(3):341-60. doi: 10.1007/s007020200028

19. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. *Eur J Pharmacol* 2004;490(1-3):115-25. doi: 10.1016/j.ejphar.2004.02.049

20. Grünblatt E, Hoyer S, Riederer P. Gene expression profile in streptozotocin rat model for sporadic Alzheimer’s disease. *J Neural Transm (Vienna)* 2004;111(3):367-86. doi: 10.1007/s00702-003-0030-x

21. de la Monte SM, Tong M. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer’s disease. *J Alzheimers Dis* 2009;17(4):817-25. doi: 10.3233/JAD-2009-1098

22. American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006. Arlington, Virginia: American Psychiatric Association; 2006.

23. Birks J. Cholinesterase inhibitors for alzheimer's disease. *Cochrane Database Syst Rev* 2006(1):CD005593. doi: 10.1002/14651858.CD005593

24. Dementia: A NICE-SR guideline on supporting people with dementia and their carers in health and social care. Leicester (UK): British Psychological Society; 2007.

25. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. *Ann Intern Med* 2008;148(5):370-8. doi: 10.7326/0003-4819-148-5-200803040-00008

26. Raine P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. *Ann Intern Med* 2008;148(5):379-97. doi: 10.7326/0003-4819-148-5-200803040-00009

27. Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the 'real-world' evidence. *Dement Geriatr Cogn Disord* 2009;28(5):389-403. doi: 10.1159/000255578

28. Tijero Berg LO, Näsland J, Lindqvist F, Johansson J, Karlström AR, Thyberg J, et al. Arrest of beta-
The effects of ectoine on Alzheimer’s disease

40. Barth S, Huhn M, Matthey B, Klimka A, Galinski EA, Engert A. Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions. *Appl Environ Microbiol* 2000;66(4):1572-9. doi: 10.1128/aem.66.4.1572-1579.2000

42. Borges N, Ramos A, Raven ND, Sharp RJ, Santos H. Comparative study of the thermostabilizing properties of mannosylglycerate and other compatible solutes on model enzymes. *Extremophiles* 2002;6(3):209-16. doi: 10.1007/s007920010236

43. Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. *Neurochem Res* 2004;29(6):1287-97. doi: 10.1023/b:nere.0000023615.89699.63

44. Chen Y, Tian Z, Liang Z, Sun S, Dai CL, Lee MH, et al. Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3Tg-AD mouse) of Alzheimer’s disease. *PLoS One* 2012;7(12):e51432. doi: 10.1371/journal.pone.0051432

45. Daneshmand P, Saliminejad K, Dehghan Shasaltaneh M, Kamali K, Riazi GH, Nazari R, et al. Neuroprotective Effects of Herbal Extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on Rat Model of Sporadic Alzheimer’s Disease. *Avicenna J Med Biotechnol* 2016;8(3):120-5.

46. Morris RG. Morris water maze. *Scholarpedia* 2008;3(8):6315. doi: 10.4249/scholarpedia.6315

47. Zhou S, Yu G, Chi L, Zhu J, Zhang W, Zhang Y, et al. Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats. *Neurotoxicology* 2013;38:136-45. doi: 10.1016/j.neuro.2013.07.007

48. Paxinos G, Watson C. The Rat Nervous Coordinates: The New Coronal Set. New York: Elsevier; 2004.

49. Guide for the care and use of laboratory animals. Washington, DC: National Academies; 1985.

50. Silver N, Cotroneo E, Proctor G, Osailan S, Paterson KL, Carpenter GH. Selection of housekeeping genes should be used as internal control? *Eur J Neurosci* 2002;6(3):209-16. doi: 10.1046/j.1460-9568.2001.01479.x

51. Arndt T. Synaptic degeneration in Alzheimer’s disease. *Acta Neuropathol* 2009;118(1):167-79. doi: 10.1007/s00401-009-0536-x
54. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. *Acta Neuropathol* 2009;118(1):53-69. doi: 10.1007/s00401-009-0486-3

55. Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: a comparative overview. *Mol Neurobiol* 2014;50(2):534-44. doi: 10.1007/s12035-014-8657-1

56. Russo I, Caracciolo L, Tweedie D, Choi SH, Greig NH, Barlati S, et al. 3,6′-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit. *J Neurochem* 2012;122(6):1181-92. doi: 10.1111/j.1471-4159.2012.07846.x

57. Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, et al. Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. *J Neuroinflammation* 2012;9:106. doi: 10.1186/1742-2094-9-106

58. Detrait ER, Danis B, Lamberty Y, Foerch P. Peripheral administration of an anti-TNF-α receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-α levels and memory deficits in mice. *Neurochem Int* 2014;72:10-3. doi: 10.1016/j.neuint.2014.04.001

59. Gabbita SP, Johnson MF, Kobritz N, Eslami P, Poteshkina A, Varadarajan S, et al. Oral TNFα Modulation Alters Neutrophil Infiltration, Improves Cognition and Diminishes Tau and Amyloid Pathology in the 3xTgAD Mouse Model. *PloS One* 2015;10(10):e0137305. doi: 10.1371/journal.pone.0137305

60. Janelssins MC, Managrello MA, Park KM, Sudol KL, Narrow WC, Oddo S, et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. *Am J Pathol* 2008;173(6):1768-82. doi: 10.2353/ajpath.2008.080528

61. Mateo I, Llorca J, Infante J, Rodríguez-Rodríguez E, Fernández-Viadero C, Pena N, et al. Low serum VEGF levels are associated with Alzheimer's disease. *Acta Neurol Scand* 2007;116(1):56-8. doi: 10.1111/j.1600-0404.2006.00775.x

62. Tang H, Mao X, Xie L, Greenberg DA, Jin K. Expression level of vascular endothelial growth factor in hippocampus is associated with cognitive impairment in patients with Alzheimer’s disease. *Neurobiol Aging* 2013;34(5):1412-5. doi: 10.1016/j.neurobiolaging.2012.10.029

63. Oosthuysse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. *Nat Genet* 2001;28(2):131-8. doi: 10.1038/88842

64. Pogue AI, Lukiw WJ. Angiogenic signaling in Alzheimer’s disease. *NeuroReport* 2004;15(9):1507-10. doi: 10.1097/01.wnr.0000130539.39937.1d

65. Pech T, Ohsawa I, Praktiknjo M, Overhaus M, Wehner S, Von Websky M, et al. A natural tetrahydropyrimidine, ectoine, ameliorates ischemia reperfusion injury after intestinal transplantation in rats. *Pathobiology* 2013;80(2):102-10. doi: 10.1159/000342792

66. Marini A, Reinelt K, Krutmann J, Bilstein A. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. *Skin Pharmacol Physiol* 2014;27(2):57-65. doi: 10.1159/000351381

67. Sydlik U, Peuschel H, Paunel-Görgülü A, Keymel S, Krämer U, Weissenberg A, et al. Recovery of neutrophil apoptosis by ectoine: a new strategy against lung inflammation. *Eur Respir J* 2013;41(2):433-42. doi: 10.1183/09031936.00132211